10:08 AM EDT, 07/05/2024 (MT Newswires) -- iTeos Therapeutics ( ITOS ) and Arcus Biosciences ( RCUS ) shares fell in early Friday trading after Roche Group's Genentech said its phase 2/3 non-small cell lung cancer study failed to meet its primary endpoints.

iTeos Therapeutics ( ITOS ) and Arcus Biosciences ( RCUS ) are also conducting separate non-small cell lung cancer studies.

Genentech said it plans to halt its study, which evaluated tiragolumab with Tecentriq and chemotherapy as first-line treatment for locally advanced unresectable or metastatic non-squamous non-small cell lung cancer.

The investigational combination therapy did not meet the primary endpoints of progression-free survival and overall survival. It also showed reduced efficacy compared to the comparator arm, Genentech said.

iTeos shares were down 9% and Arcus shares were 4.8% lower in recent trading.

Price: 13.44, Change: -1.34, Percent Change: -9.05